Sort
4,870 grants matching “glp 1”
PLT+ Characterization and IND-Enabling Studies
$952,100Bradford Dykstra · Stellular Bio, Inc. · R44 · FY2021 · HL
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)
$950,520Zhiyong Yang · Fzata, Inc. · R44 · FY2023 · DK
Ambient light activatable opsin based therapy for age-related macular degeneration
$950,373Samarendra Kumar Mohanty · Nanoscope Technologies, Llc · R44 · FY2019 · EY
A Novel Probiotic for the Treatment of Sjogren's Syndrome
$949,519Gary Fanger · Rise Therapeutics, Llc · R44 · FY2020 · DE
Vision Restoration with Photoswitch Technology
$948,543Jay K Trautman · Photoswitch Biosciences, Inc. · R44 · FY2015 · EY
Protein therapeutic to facilitate healing of chronic wounds.
$948,478Tao Tan · Trim-Edicine, Inc. · R44 · FY2020 · GM
A Novel Probiotic for the Treatment of Sjogren's Syndrome
$947,701Gary Fanger · Rise Therapeutics, Llc · SB1 · FY2023 · DE
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses
$947,203John H Eldridge · Profectus Biosciences, Inc. · R01 · FY2015 · AI
Oral PCSK9/LDLR antagonist direction to the clinic
$945,393Nabil A Elshourbagy · Shifa Biomedical Corporation · R44 · FY2021 · HL
Lead Optimization and Preclinical Development of a small molecule inhibitor of M. avium KasA
$944,067David Alland · Hackensack University Medical Center · U19 · FY2025 · AI
Oral PCSK9/LDLR antagonist direction to the clinic
$943,895Nabil A Elshourbagy · Shifa Biomedical Corporation · R44 · FY2020 · HL
Design And Development Of Experimental Therapeutics
$943,412Nigel H. Greig · National Institute On Aging · Z01 · FY2008 · AG
Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility
$942,701Bruce Dale Weintraub · Trophogen, Inc. · R44 · FY2019 · HD
Critical Path IND-enabling Studies, Regulatory, and Product Development
$942,042Robert Walter Buckheit · Imquest Biosciences · U19 · FY2012 · AI
Primary-care strategies to enhance weight management after discontinuation of anti-obesity medications
$942,000Melissa Marie Crane · Rush University Medical Center · R01 · FY2025 · DK
Novel rifamycins to improve cure rates and shorten treatment of M. abscessus lung disease
$941,394Thomas Dick · Hackensack University Medical Center · U19 · FY2025 · AI
Pudendal neuromodulation for urinary and fecal incontinence and sphincter dyssynergia
$941,206Karl B Thor · Dignify Therapeutics, Llc · R44 · FY2020 · NS
Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents
$939,827Dennis Liang Fei · Stemsynergy Therapeutics, Inc. · R44 · FY2023 · CA
Lentivirus-based Immunogene Therapy for HIV Infection
$939,640University Of Pennsylvania · U19 · FY2005 · AI
Hybrid Molecules Designed to Enhance Antibiotic Activity
$939,605George E Wright · Glsynthesis, Inc. · R44 · FY2007 · AI
Critical Path IND-enabling Studies, Regulatory, and Product Development
$939,369Robert Walter Buckheit · Imquest Biosciences · U19 · FY2013 · AI
Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis
$939,151Aaron Richard McCabe · Minnetronix, Inc. · R42 · FY2020 · AI
Subcutaneous Acute Ischemia Monitor
$938,939Dave Lawrence Keenan · Angel Medical Systems, Inc. · R44 · FY2015 · HL
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
$938,597Christopher D Pack · Metaclipse Therapeutics Corporation · R44 · FY2022 · CA
Hybrid Molecules Designed to Enhance Antibiotic Activity
$938,275George E Wright · Glsynthesis, Inc. · R44 · FY2006 · AI